Guadecitabine (SGI-110, S-110) is a next-generation hypomethylating agent used for its prolonged in vivo exposure of the active metabolite decitabine compared to intravenous decitabine; it reduces DNA methylation levels and depletes DNMT1 in cancer cells; it inhibits colony formation in T24 bladder cancer cells; it induces strong p16 expression and demethylates the p16 gene promoter region; it exhibits immunomodulatory activity by upregulating cancer/testis antigens (CTAs) such as MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A10, GAGE1-2, GAGE1-6, NY-ESO-1, and SSX1-5 at both mRNA and protein levels in various tumor cell lines (including melanoma, mesothelioma, renal cell carcinoma, and sarcoma); it enhances tumor cell recognition by gp100-specific cytotoxic T lymphocytes (CTLs) through upregulation of HLA class I antigens and ICAM-1; it demonstrates antitumor efficacy in human xenograft models by suppressing tumor cell growth.